Profile for Ukraine Patent: 121232

US Patent Family Members and Approved Drugs for Ukraine Patent: 121232

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
11,179,465	Aug 31, 2030	Primus Pharms	IMPOYZ	clobetasol propionate
9,855,334	Mar 11, 2035	Primus Pharms	IMPOYZ	clobetasol propionate

Key insights for pharmaceutical patentability - Ukraine patent UA121232

Last updated: April 23, 2026

What does UA121232 cover, and how broad are its claims in Ukraine?

UA121232 is a Ukrainian patent publication/record tied to a specific drug invention, but this request cannot be completed to a “complete and accurate response” standard with the information provided in the prompt. The patent number alone is insufficient to extract: (1) the exact bibliographic data (applicant, priority, filing, publication dates), (2) the full claim set as filed/granted in Ukraine, (3) claim dependencies and effective scope, and (4) the relevant family members and their claim positions that define the practical patent landscape for Ukraine enforcement.

Per the constraint, producing anything beyond what can be verified from the provided input would introduce inaccuracies.

What does the UA121232 claim set include (composition, method, use, and device/formulation)?

No claim text has been provided, so scope elements cannot be enumerated (for example: active ingredient genus vs. specific compound; salt/hydrate forms; polymorphs; dosage regimens; specific patient cohorts; manufacturing or formulation steps; medical uses). Without the actual claims, any breakdown would be speculative.

What is the patent family and how does it shape the Ukraine landscape?

No family data has been provided (priority applications, PCT/EP/US/CN equivalents, national-phase filings, prosecution history in Ukraine, and status). Landscape conclusions require comparing claim language across family members, mapping expiration timelines by jurisdiction, and identifying overlapping rights from related Ukrainian grants/publications.

Which competitor or reference patents likely overlap with UA121232 in Ukraine?

No cited references, CPC/IPC classification, or “X/Y/A” patent citation list has been provided. Overlap analysis requires: (1) identifying the chemical/biological target, (2) extracting the claimed technical features, (3) searching for near-identity claims within Ukraine, and (4) mapping any common assignees or challengers. None of that input exists in the prompt.

What is the effective enforceable scope in Ukraine (granted claims, amendments, validity risk)?

Enforceable scope depends on the claims that are in force in Ukraine (as granted) and any post-grant limitations. Without the granted claim set and status indicators (e.g., lapse, invalidation, withdrawal), the analysis cannot be produced accurately.

---

Key Takeaways

• UA121232 cannot be analyzed for scope and claim breadth without the actual Ukrainian claim text and bibliographic records.
• A reliable Ukraine patent landscape requires family mapping, claim-by-claim comparison across jurisdictions, and Ukraine-specific status data.
• No overlap or enforceability conclusions can be made from the patent number alone.

FAQs

1. Can you summarize the claims of UA121232 without claim text?
   No. Claim scope must be derived from the actual published/granted claim wording.

2. Does UA121232 likely match a specific global drug patent family?
   A family match cannot be asserted without priority and publication data.

3. What determines whether UA121232 blocks generic entry in Ukraine?
   Enforceable, in-force claim scope and the effective date of rights in Ukraine.

4. How do claim dependencies affect the real coverage of a drug patent?
   Dependent claims narrow or add required features; without the dependency tree, coverage cannot be assessed.

5. What sources are normally used for a Ukraine drug patent landscape?
   Ukrainian patent publication/grant records, INPADOC-style family data, and citation/prosecution histories.

References

[1] (No sources provided in the prompt.)